<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336095">
  <stage>Registered</stage>
  <submitdate>15/10/2010</submitdate>
  <approvaldate>21/10/2010</approvaldate>
  <actrnumber>ACTRN12610000898055</actrnumber>
  <trial_identification>
    <studytitle>The use of non invasive methods to predict drug handling and toxicity of Irinotecan</studytitle>
    <scientifictitle>The utility of genomics and functional imaging to predict Irinotecan pharmacokinetics and pharmacodynamics: The PREDICT Irinotecan Study</scientifictitle>
    <utrn />
    <trialacronym>The PREDICT IR study</trialacronym>
    <secondaryid>PMCC Protocol No 10/55</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Locally advanced, recurrent or metastatic colorectal adenocarcinoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Standard treatment of FOLFIRI or FOLFIRI-Avastin regimen for the period of 8 weeks
The Irinotecan will be given over 90 minutes followed by Leucovorin given intravenously over 2 hours and immediately followed by Avastin given over 1 hour if the doctor decides to combine it with FOLFIRI. 5FU will be given intravenously by rapid injection and then 5FU will be given over 46 hrs through a pump connected to the PORT/PICC. Patient will be educated about the care of the PICC or PORT and the pump. The pump will be disconnected at the end of the 46 hours performed at patient home.

Total duration of the study 4 years</interventions>
    <comparator>N/A</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Response assessment in the first 4 courses of treatment
using computed tomography (CT) scan and/or magnetic resonance imaging (MRI) and/or positron emission tomography (PET) and/or X-Ray and clinical examination.</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Correlations between functional imaging and PK
and  between functional imaging and Toxicity
Associations will be assessed to examine the strength and direction of the linear relationship between HFI with PK and toxicity parameters. The Pearson correlation coefficient (for normally distributed variables) or nonparametric Spearman rank correlation (for any non-normally distributed variables) will be calculated with the correlation (r2) and p-value reported. Linear regression models to predict PK parameters from HFI parameters will be fitted to estimate the relationship between pairs of parameters identified as having a significant correlation coefficient. Logistic regression will be used to assess whether HFI parameters can predict presence or absence of grade delayed diarrhoea and neutropenia.</outcome>
      <timepoint>In the 4th year of the project</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Correlations of genetic factors, with PK, toxicity and response
SNP genotypes will be assessed for deviations from Hardy-Weinberg equilibrium. Fisher's exact test or Pearson's chi-square test will be used, as appropriate, to assess the association between SNP genotypes with toxicity and objective response in 2 degree of freedom tests. Linear and logistic regressions will be used to assess the relationship between the number of minor alleles at each SNP with pharmacokinetic, toxicity and response parameters, as appropriate, in 1 degree of freedom tests.</outcome>
      <timepoint>In the 4th year of the project</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Nil</outcome>
      <timepoint>Nil</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Histologically/cytologically confirmed locally advanced, recurrent  or metastatic colorectal adenocarcinoma not amenable to surgery or radiation therapy with curative intent, eligible for first-line or second-line chemotherapy with Irinotecan-5FU (FOLFIRI regimen or FOLFIRI-Bevacizumab [Avastin]); measurable or evaluable disease, adequate hepatic, bone marrow and renal function, Eastern Cooperative Oncology Group (ECOG) 2 or less, life expectancy greater than 12 weeks, written informed consent for the study and its associated procedures.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Evidence of severe or uncontrolled systemic disease or any concurrent condition which in the investigator's opinion makes it undesirable for the patient to participate in the study or which would jeopardize compliance with the protocol or compromises the patient's ability to give informed consent.
Female patients who are pregnant or breast-feeding.
Any unresolved toxicity greater than NCI-CTC Grade 2 from previous anti-cancer therapy, active liver disease (e.g. chronic active hepatitis, cirrhosis), known diagnosis of human immunodeficiency virus (HIV) infection or Gilberts syndrome, prior severe reaction of fluoropyrimidine therapy, known sensitivity to 5-FU or deficit of dihydropyrimidine-dehydrogenase (DPD)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs>Natural history</purposeobs>
    <duration>Longitudinal</duration>
    <selection>Defined population</selection>
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/11/2010</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <postcode>3002</postcode>
    <postcode>3050</postcode>
    <postcode>3084</postcode>
    <postcode>3011</postcode>
    <postcode>3128</postcode>
    <postcode>3199</postcode>
    <postcode>5042</postcode>
    <postcode>5011</postcode>
    <postcode>2065</postcode>
    <postcode>2217</postcode>
    <postcode>2050</postcode>
    <postcode>2139</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Peter MacCallum Cancer Centre</primarysponsorname>
    <primarysponsoraddress>St Andrew's Place, East Melbourne, VIC, 3002</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council of Australia</fundingname>
      <fundingaddress>Level 1
16 Marcus Clarke Street
Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof. Michael Jefford</othercollaboratorname>
      <othercollaboratoraddress>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, 3002, VIC</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof J Zalcberg</othercollaboratorname>
      <othercollaboratoraddress>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, 3002, VIC</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr C Cullinane</othercollaboratorname>
      <othercollaboratoraddress>Translational Research Laboratory
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, 3002, VIC</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof Ian Campbell</othercollaboratorname>
      <othercollaboratoraddress>Cancer Genetics
Peter MacCallum Cancer Centre 
St Andrew's Place, East Melbourne, 3002, VIC</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof. N Tebbutt</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
Austin Hospital
Studley Road, Heidelberg Heights, VIC, 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof A Scott</othercollaboratorname>
      <othercollaboratoraddress>Dept of Nuclear Medicine and Ludwig Institute
Studley Road, Heidelberg Heights, VIC, 3084</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof L Lipton</othercollaboratorname>
      <othercollaboratoraddress>Medical Oncology and Clinical Haematology Unit
Western Hospital
Gordon Street, Footscray, VIC, 3011</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr J Desai</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
Peter MacCallum Cancer Centre 
St Andrew's Place, East Melbourne, VIC, 3002</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Vinod Ganju</othercollaboratorname>
      <othercollaboratoraddress>Department of Medical Oncology
Peninsula Oncology Centre 
24-28 Frankston-Flinders Road, Frankston, VIC, 3199</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Phillip Parente</othercollaboratorname>
      <othercollaboratoraddress>Department of Medical Oncology
Box Hill Hospital
Nelson Road, Box Hill, VIC, 3128</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assco Prof Joe McKendrick</othercollaboratorname>
      <othercollaboratoraddress>Department of Medical Oncology
Box Hill Hospital
Nelson Road, Box Hill, VIC, 3128</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof Sue-Anne McLachlan</othercollaboratorname>
      <othercollaboratoraddress>St Vincent's Hospital
41 Victoria Parade, Fitzroy, VIC, 3065</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Prof S Clarke</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medicine and Medical Oncology
Concord Hospital
Hospital Road, Concord, NSW, 2139</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof L Hovarth</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
Royal Prince Alfred Hospital 
Missenden Road, Camperdown, NSW, 2050</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr W Liauw</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
St Georges Hospital
Gray Street, Kogarah, NSW, 2217</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof M Links</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology 
Royal North Shore Hospital
Pacific Highway, St Leonards, NSW, 2065</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr N Pavlakis</othercollaboratorname>
      <othercollaboratoraddress>Dept Medical Oncology
Queen Elizabeth Hospital
Woodville Road, Woodville, SA, 5011</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Assoc Prof T Price</othercollaboratorname>
      <othercollaboratoraddress>Dept Medical Oncology
Flinders Medical Centre
Flinders Drive, Bedford Park, SA, 5042</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr C Karapetis</othercollaboratorname>
      <othercollaboratoraddress>Dept of Medical Oncology
Flinders Medical Centre  
Flinders Drive, Bedford Park, SA, 5042</othercollaboratoraddress>
      <othercollaboratorcountry>Australia</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Observational pharmacology/pharmacogenomic/imaging study in patients receiving standard FOLFIRI ± Avastin for advanced incurable colorectal cancer. 
Patients will undergo baseline nuclear hepatic functional imaging with IDA scans and bloods will be taken for metabolic/pharmacodynamic pharmacogenomics. 
Bloods will be taken for Irinotecan PK in course 1. 
Toxicities will be documented in the first 4 cycles and patients will be restaged at the end of cycle 4 (i.e. 8 weeks).
No trial involvement beyond 4 cycles is required and treatment beyond this point will be at the discretion of the treating clinician.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Peter MacCallum Cancer Centre Ethics Committee</ethicname>
      <ethicaddress>Level 4, 10 St Andrews Place	                      
East Melbourne, Victoria, 3002</ethicaddress>
      <ethicapprovaldate>31/08/2010</ethicapprovaldate>
      <hrec>PMCC Protocol No 10/55</hrec>
      <ethicsubmitdate>7/07/2010</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Assoc Prof M Michael</name>
      <address>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, 3002, VIC</address>
      <phone>+61 3 96561159</phone>
      <fax>+61 3 96561408</fax>
      <email>Michael.Michael@petermac.org</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Assoc Prof M Michael</name>
      <address>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, 3002, VIC</address>
      <phone>+61 3 96561159</phone>
      <fax>+61 3 96561408</fax>
      <email>Michael.Michael@petermac.org</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Assoc Prof M Michael</name>
      <address>Division of Haematology and Medical Oncology
Peter MacCallum Cancer Centre
St Andrew's Place, East Melbourne, 3002, VIC</address>
      <phone>+61 3 96561159</phone>
      <fax>+61 3 96561408</fax>
      <email>Michael.Michael@petermac.org</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>